Wed, Apr 23, 2014, 1:29 PM EDT - U.S. Markets close in 2 hrs 31 mins

Recent

% | $
Quotes you view appear here for quick access.

BB&T Corporation Message Board

pksgrady 6 posts  |  Last Activity: Feb 10, 2014 5:49 PM Member since: Mar 27, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    "EARNINGS"

    by dcr82160 Feb 6, 2014 7:22 PM
    pksgrady pksgrady Feb 10, 2014 5:49 PM Flag

    Whisper number is $1,28 vs. 0.99 consensus estimate. It will be interesting what they report and if the number is sufficient to ease concern about higher administrative and R&D cost (building the pipeline).

  • pksgrady pksgrady Feb 6, 2014 4:59 PM Flag

    I agree with you, but I'm looking at EMA 20 & 50. It hit the 20 today and most likely will bounce off and take off from here. One concern however is the overall weakness in the bio-tech sector.

    http://investing.money.msn.com/investments/charts?symbol=US:GILD#{"events":["earnings"],"zRange":"6","startDate":"2013-2-6","endDate":"2014-2-6","chartStyle":"mountain","chartCursor":"1","scaleType":"0","yaxisAlign":"right","indicators":[["EMA",20,50,200]],"mode":"pan"}

  • Will hit 90 and 100 real quick!!!!

    Deutsche raised price target a few days ago to 132
    http://www.streetinsider.com/Analyst+Comments/Biogen+(BIIB),+Celgene+(CELG),+and+Gilead+(GILD)+Price+Targets+Raised+at+Deutsche+Bank/9093667.html

    Today Baird raised their target to 102
    http://blogs.barrons.com/stockstowatchtoday/2014/02/04/gilead-sciences-sovaldi-a-blockbuster-baird-sees-30-upside/?mod=yahoobarrons&ru=yahoo

    Sentiment: Strong Buy

  • pksgrady pksgrady Feb 1, 2014 2:29 PM Flag

    I rather look at conservative numbers and be positively surprise than the opposite

  • pksgrady pksgrady Jan 30, 2014 5:49 PM Flag

    If we are talking numbers we should go the whole nine yards

    Skin infections, the market for Brilacidin is roughly a $17 bill./year market in U.S.
    Capturing just 6% of that market would translate into 1 bill of sales. Price to Sales ratio could range from 4 - 14, which would translate to a market cap of 4 - 14 bill, which would roughly translate into a stock price of $ 20 - % 70.

    Similar calculations for the other areas support the above listed stock prices.
    The market for cancer drugs is roughly $77.4bn. CTIX just need to capture a fraction of that.

    Prurisol could generate anything from 100 - 500 mill, if the drug is shows modest activities; if exceptional it could easily generate of a bill.

    I don't think CTIX will trade much longer in the 1.5 - 2 range (150 - 200 market cap). Modest good news could easily push the stock into the $5 (500 mill market cap) range this year, into the $ 20 (2 bill market cap) range next year. And that still looks cheap.

    Of course there are risks along the way otherwise would could just wait and harvest our money tree as I mentioned before.

    Of course that's all my 2 cents and nobody should make investment decisions based on my numbers.

  • I've established a position a while back. It's not large in Dollar amounts, but large enough that it could amount to a significant gain if CTIX really advances like some of the above companies.

    Of course there is a lot of risks, otherwise everybody would just buy and wait to harvest from the money tree.

    However it seems the drug pipeline is getting really rich and if one compound does not succeed another may does.

    Of course another possibility could be a buy-out. That would happen once it's clear a compound is succeeding as the larger companies reduce their risks that way.

BBT
37.94-0.17(-0.43%)1:28 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.